Wealth Enhancement Advisory Services’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.85M Buy
70,797
+24,132
+52% +$1.65M ﹤0.01% 1627
2026
Q1
$1.04M Buy
46,665
+25,479
+120% +$1.8M ﹤0.01% 1770
2025
Q4
$1.61M Sell
21,186
-6
-0% -$404 ﹤0.01% 1648
2025
Q3
$1.4M Buy
21,192
+7,021
+50% +$466K ﹤0.01% 1653
2025
Q2
$765K Sell
14,171
-6,649
-32% -$378K ﹤0.01% 1909
2025
Q1
$1.33M Buy
20,820
+8,341
+67% +$485K ﹤0.01% 1456
2024
Q4
$597K Buy
12,479
+869
+7% +$44.6K ﹤0.01% 1855
2024
Q3
$665K Sell
11,610
-161
-1% -$9.23K ﹤0.01% 1633
2024
Q2
$616K Buy
11,771
+1,554
+15% +$68.2K ﹤0.01% 1514
2024
Q1
$416K Buy
+10,217
New +$383K ﹤0.01% 1703
2023
Q4
Sell
-9,606
Closed -$367K 2383
2023
Q3
$367K Buy
+9,606
New +$394K ﹤0.01% 1616

Other funds holding HALO

Wealth Enhancement Advisory Services's HALO Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Halozyme (HALO) stake by 52% in Q2 2026, buying an estimated $1.65M and bringing the position to 70,797 shares worth $1.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

Wealth Enhancement Advisory Services first reported a position in HALO in Q3 2023 and has held it in 11 quarters since. 137 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Wealth Enhancement Advisory Services held 70,797 shares of Halozyme worth $1.85M as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 24,132 Halozyme shares in Q2 2026, an estimated $1.65M.
  • Halozyme made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #1627 holding.
  • Wealth Enhancement Advisory Services first reported a position in Halozyme in Q3 2023 and has held it in 11 quarters since.
  • 137 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.